Literature DB >> 21378323

Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium.

Tobias Weissenbacher1, Christina Kuhn, Doris Mayr, Roman Pavlik, Klaus Friese, Christoph Scholz, Udo Jeschke, Nina Ditsch, Darius Dian.   

Abstract

BACKGROUND: The potential mechanism of malignant transformation from leiomyoma to leiomyosarcoma is still debated. The aim was the evaluation of expression patterns of mucin-1 (MUC1) (MUC1 VU-4-H5), galectin-1 (Gal-1) and galectin-3 (Gal-3) in human myometrium and leiomyoma and in comparison to leiomyosarcoma.
MATERIALS AND METHODS: Myometrium, leiomyoma and leiomyosarcoma tissues were obtained from 79 patients. Samples were analyzed regarding the expression of MUC1, Gal-1 and Gal-3 by immunohistochemical staining of paraffin-embedded material.
RESULTS: The expression of MUC1 (VU4-H5) was up-regulated in leiomyoma (p = 0.065) and leiomyosarcoma (p = 0.039) as compared to the myometrium. In contrast, there were no significant differences in expression of Gal-3 in the tissues from the myometrium, myoma and leiomyosarcoma. Concerning Gal-1 expression, the differences were not significant comparing myometrium and leiomyosarcoma (p = 0.277). Myoma had elevated levels of Gal-1 compared to myometrium (p = 0.007) and leiomyosarcoma (p < 0.0001).
CONCLUSION: MUC1 and Gal-1 might be useful for evaluating the potential of leiomyoma to transform into leiomyosarcoma and, therefore, help in risk-adapted consultation and adjusted treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378323

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Authors:  Anke Vanderstraeten; Catherine Luyten; Godelieve Verbist; Sandra Tuyaerts; Frederic Amant
Journal:  Cancer Immunol Immunother       Date:  2014-06       Impact factor: 6.968

Review 3.  The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.

Authors:  Piotr Rubisz; Michał Ciebiera; Lidia Hirnle; Magdalena Zgliczyńska; Tomasz Łoziński; Piotr Dzięgiel; Christopher Kobierzycki
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

4.  Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.

Authors:  Kenichi Makino; Kazuhiro Kawamura; Wataru Sato; Nanami Kawamura; Toshio Fujimoto; Yukihiro Terada
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

5.  Analysis of Epithelial Growth Factor-Receptor (EGFR) Phosphorylation in Uterine Smooth Muscle Tumors: Correlation to Mucin-1 and Galectin-3 Expression.

Authors:  Tobias Weissenbacher; Thomas Vrekoussis; David Roeder; Antonis Makrigiannakis; Doris Mayr; Nina Ditsch; Klaus Friese; Udo Jeschke; Darius Dian
Journal:  Int J Mol Sci       Date:  2013-02-28       Impact factor: 5.923

Review 6.  Exploiting poly(I:C) to induce cancer cell apoptosis.

Authors:  Francesca Bianchi; Samantha Pretto; Elda Tagliabue; Andrea Balsari; Lucia Sfondrini
Journal:  Cancer Biol Ther       Date:  2017-09-07       Impact factor: 4.742

Review 7.  Galectin-3: an immune checkpoint target for musculoskeletal tumor patients.

Authors:  Kosei Nakajima; Vitaly Balan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2020-09-14       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.